Cardiogen
aka Ala-Glu-Asp-Arg
Mechanism
Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg / AEDR) from the Khavinson bioregulator series, studied in Russian preclinical models for potential effects on cardiac-tissue gene expression and cardiomyocyte structural proteins. Not FDA-approved; no Western clinical trials have been performed, and all published evidence originates from a single research group.
Identification
| Molecular formula | C18H31N7O9 |
|---|---|
| Sequence | AEDR |
| Typical dose | 200-400 mcg/day oral (capsule) or 1-2 mg/day subcutaneous, in 10-30 day cycles repeated 2-3 times per year |
| Half-life | Not formally characterized; estimated minutes in plasma (typical for unprotected tetrapeptides) |
Vendors selling Cardiogen
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| BioLongevity Labs | 20 mg | $69.97 | — | 96 |
| Orbitrex Peptides | 20 mg | $149.99 | — | 95 |
| Peptide Tech | 20 mg | $48.99 | — | 94 |
| Mile High Compounds | — | $49.99 | — | 94 |
| Skye Peptides | 25 mg | $59.00 | — | 90 |
| Peptidology | 20 mg | $54.99 | — | 89 |
| Verified Peptides | 20 mg | $55.00 | — | 86 |
| Peptidegurus | 20 mg | — | — | 84 |
| Peptidegurus | 20 mg | — | — | 84 |
| Cocer Peptides | 20 mg | $160.00 | — | 82 |
| Certified Peptides | 20 mg | $105.00 | — | 62 |
| Atomik Labz | 20 mg | $65.00 | — | — |
| Biotech Peptides | 20 mg | $62.00 | — | — |
| Core Peptides | 20 mg | $75.00 | — | — |
| Modern Research Peptides | 20 mg | $49.99 | — | — |
| Paramount Peptides | 20 mg | $80.00 | — | — |
| Peptide Crafters | 25 mg | $55.00 | — | — |
| Solution Peptides | 20 mg | $65.00 | — | — |
| Wellness Peptides | — | $60.00 | — | — |
Research
Aims Sex differences in transthyretin cardiac amyloidosis (ATTR-CM) are increasingly recognised; however, women are underrepresented in trials and sex-specific treatment effects remain incompletely understood. We evaluated sex differences in baseline phenotype, outcomes and vutrisiran response in ATTR-CM.
source →Aims Post-capillary pulmonary hypertension (pcPH) is a frequent complication of heart failure (HF), associated with poor outcomes.
source →This clinical consensus statement, developed by the Heart Failure Association of the European Society of Cardiology, offers a detailed review of the non-specific management of transthyretin amyloid cardiomyopathy (ATTR-CM).
source →Musculoskeletal manifestations of transthyretin amyloidosis (ATTR) are common, early in the disease course (usually years before cardiac involvement), and are potentially predictive.
source →Background Diagnosis of cardiac amyloidosis (CA) is complex and implicates several medical specialists. CA is usually suspected based on symptoms ('red flags') and non-invasive imagery. Early diagnosis and appropriate treatment are critical in patients with CA.
source →Background Guidelines recommend screening for transthyretin amyloid cardiomyopathy (ATTR-CM) after age 65 years, yet some patients are diagnosed earlier.
source →Background/Objectives: Carpal tunnel syndrome (CTS) may signal extracardiac amyloid deposition years before transthyretin cardiac amyloidosis (ATTR-CA). This study investigated potential alterations of wrist tissue T1 values in ATTR-CA patients.
source →Transthyretin amyloidosis (ATTR) is a severe and rare disease characterized by the progressive deposition of misfolded transthyretin proteins, causing irreversible organ damage. Transthyretin amyloidosis can present as a hereditary ATTR or acquired wild-type ATTR form.
source →Background Effective physician-patient communication is crucial to compassionate healthcare, particularly when conveying life-altering diagnoses such as those associated with congenital heart diseases. Despite its importance, medical practitioners often face challenges in communicating effectively.
source →This Phase 1b/2a open-label study is designed to assess the safety and efficacy of genistein in patients with heart failure (HF). The investigation will focus on its impact on inflammatory and cardiometabolic biomarkers, as well as its effects on cardiac function and exercise capacity.
source →Sinus venosus defect (SVD) accounts for 10% of atrial septal defects and is characterized by an anomalous pulmonary venous return in the superior vena cava associated with a high situated atrial septal defect. Since 2013, transcatheter correction of this congenital heart disease has emerged as a new treatment option.
source →Participants are being recruited at the inpatient department of the National Medical Research Center of Cardiology on a 'all-comers' basis. The enrolled participants will be divided into the main group (diagnosed with atherosclerotic cardiovascular disease (ASCVD)) and control (not diagnosed with ASCVD).
source →This study will be performed at clinical sites that have administered CardioGen-82® to patients from January to July 2011.
source →